Article Text

Download PDFPDF
Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
  1. L Razzaq1,
  2. R J W de Keizer1,2
  1. 1Department of Ophthalmology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
  2. 2Department of Ophthalmology, Antwerp University Hospital (UZA), Antwerp, Belgium
  1. Correspondence to Rob J W de Keizer, Department of Ophthalmic Oncology, LUMC, Albinusdreef 2, 2300 RC, Leiden, The Netherlands; r.j.w.de_keizer{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Treatment options for iris and anterior ciliary body melanoma include local resection, plaque radiation therapy, proton beam therapy and, for diffuse cases, enucleation.1–3

A radioactive plaque is placed directly over the cornea, but this irradiation may damage the limbal stem cells or corneal epithelial cells, which may lead to ocular surface disease, including dry-eye problems.4 5 Such problems have been reported after the treatment of uveal melanomas with plaque therapy, proton beam radiotherapy and stereotactic radiotherapy.6–8 We determined whether treatment of anterior melanoma with Ruthenium-106 plaque therapy induced complaints and clinical signs of dry eyes.

Materials and methods

Between 1997 and August 2008, a total of 39 patients with iris and/or anterior ciliary body melanomas were treated with Ru-106 radiation therapy at the LUMC; 23 patients were seen for follow-up …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.